Literature DB >> 31832109

Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice.

Rostyslav Bubnov1,2, Lidiia Babenko1, Liudmyla Lazarenko1, Maryna Kryvtsova1, Oleksandr Shcherbakov1, Nadiya Zholobak1, Olga Golubnitschaja3,4,5, Mykola Spivak1,6.   

Abstract

BACKGROUND: Microbiome modulation is a pillar intervention to treat metabolic syndrome, prestages, and cascade of related pathologies such as atherosclerosis, among others. Lactobacillus and Bifidobacterium probiotic strains demonstrate efficacy to reduce obesity, dyslipidemia, and improve metabolic health. Novel prebiotic substances composed with known probiotics may strongly synergize health benefits to the host. The aim of this study was to evaluate beneficial effects of Lactobacillus and Bifidobacterium strains (probiotics) if composed with nanoceria (potential prebiotic) to reduce cholesterol levels and restore gut microbiota in obese mice.
MATERIALS AND METHODS: Two lines of mice were used in the study: BALB/c mice (6-8 weeks, 18-24 g) and CBA mice (11-12 months, 20-26 g); experimental animals were fed by fat-enriched diet 3 weeks before the evaluation. Animals were divided into groups to test probiotic strains and nanoceria. All groups received probiotic strains orally and cerium dioxide orally or intravenously in various composition. A group of untreated animals was used as a control. Cholesterol level and gut microbiota of mice were studied.
RESULTS: Cerium dioxide nanoparticles, probiotic strain L. casei ІМV В-7280, and composition B. animalis VKB/B. animalis VKL applied separately and in different combinations all reduced at different levels free and bound cholesterol in blood serum of mice fed by fat-enriched diet. The combination of 0.01 M nanoceria and probiotic strain L. casei ІМV В-7280 resulted in the fastest cholesterol level decrease in both young and mature animals. Oral administration of CeO2 applied alone reduced the number of microscopic fungi in the gut of mice and Gram-positive cocci (staphylococci and/or streptococci). Application of L. casei IMV B-7280 as a probiotic strain increased most significantly the number of lactobacilli and bifidobacteria in the gut of mice. The most significant normalization of gut microbiota was observed after oral administration of alternatively either L. casei IMV B-7280 + 0.1 M CeO2 or L. casei IMV B-7280 + 0.01 M CeO2.
CONCLUSION: Dietary application of nanoceria combined with probiotic strains L. casei IMV B-7280, B. animalis VKB, and B. animals VKL has significantly reduced both free and bound cholesterol levels in serum. Simultaneous administration of probiotics and cerium nanoparticles as a prebiotic, in various combinations, significantly enhanced positive individual effects of them on the gut microbiota spectrum. The presented results provide novel insights into mechanisms behind nutritional supplements and open new perspectives for application of probiotics combined with substances demonstrating prebiotic qualities benefiting, therefore, the host health. Follow-up translational measures are discussed to bring new knowledge from lab to the patient. If validated in a large-scale clinical study, this approach might be instrumental for primary and secondary prevention in obese individual and patients diagnosed with diabetes. To this end, individualized prediction and treatments tailored to the person are strongly recommended to benefit the health condition of affected individuals. © European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2019.

Entities:  

Keywords:  Animal model; Atherosclerosis; Bifidobacterium; Cholesterol; Gut microbiota; Improved metabolism; In vivo; Lactobacillus; Metabolic syndrome; Microbiome; Nanoceria; Nanoparticles; Obesity; Phenotype; Prebiotic; Predictive preventive personalized medicine; Probiotic

Year:  2019        PMID: 31832109      PMCID: PMC6882984          DOI: 10.1007/s13167-019-00190-1

Source DB:  PubMed          Journal:  EPMA J        ISSN: 1878-5077            Impact factor:   6.543


  80 in total

Review 1.  Inflammation and metabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

2.  Selection of potential probiotic lactobacilli for cholesterol-lowering properties and their effect on cholesterol metabolism in rats fed a high-lipid diet.

Authors:  J Wang; H Zhang; X Chen; Y Chen; Q Bao
Journal:  J Dairy Sci       Date:  2012-04       Impact factor: 4.034

3.  Effect of Lactobacillus acidophilus NS1 on plasma cholesterol levels in diet-induced obese mice.

Authors:  M Song; S Park; H Lee; B Min; S Jung; S Park; E Kim; S Oh
Journal:  J Dairy Sci       Date:  2014-10-30       Impact factor: 4.034

4.  Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology.

Authors:  Mykola Ya Spivak; Rostyslav V Bubnov; Ilya M Yemets; Liudmyla M Lazarenko; Natalia O Tymoshok; Zoia R Ulberg
Journal:  EPMA J       Date:  2013-07-29       Impact factor: 6.543

5.  Bile resistance mechanisms in Lactobacillus and Bifidobacterium.

Authors:  Lorena Ruiz; Abelardo Margolles; Borja Sánchez
Journal:  Front Microbiol       Date:  2013-12-24       Impact factor: 5.640

Review 6.  Discovering probiotic microorganisms: in vitro, in vivo, genetic and omics approaches.

Authors:  Konstantinos Papadimitriou; Georgia Zoumpopoulou; Benoit Foligné; Voula Alexandraki; Maria Kazou; Bruno Pot; Effie Tsakalidou
Journal:  Front Microbiol       Date:  2015-02-17       Impact factor: 5.640

7.  Identification of lactate dehydrogenase as a mammalian pyrroloquinoline quinone (PQQ)-binding protein.

Authors:  Mitsugu Akagawa; Kenji Minematsu; Takahiro Shibata; Tatsuhiko Kondo; Takeshi Ishii; Koji Uchida
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

Review 8.  Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.

Authors:  Krithika Srikanthan; Andrew Feyh; Haresh Visweshwar; Joseph I Shapiro; Komal Sodhi
Journal:  Int J Med Sci       Date:  2016-01-01       Impact factor: 3.738

9.  Transitions from Ideal to Intermediate Cholesterol Levels may vary by Cholesterol Metric.

Authors:  Joseph C Engeda; Katelyn M Holliday; Shakia T Hardy; Sujatro Chakladar; Dan-Yu Lin; Gregory A Talavera; Barbara V Howard; Martha L Daviglus; Amber Pirzada; Pamela J Schreiner; Donglin Zeng; Christy L Avery
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

10.  Comparative study of probiotic effects of Lactobacillus and Bifidobacteria strains on cholesterol levels, liver morphology and the gut microbiota in obese mice.

Authors:  Rostyslav V Bubnov; Lidiia P Babenko; Liudmyla M Lazarenko; Viktoria V Mokrozub; Oleksandr A Demchenko; Oleksiy V Nechypurenko; Mykola Ya Spivak
Journal:  EPMA J       Date:  2017-10-10       Impact factor: 6.543

View more
  11 in total

1.  A κ-OR Agonist Protects the Endothelial Function Impaired by Hyperuricemia Through Regulating the Akt/eNOS Signal Pathway.

Authors:  Qin Zheng; Qi Wu; Hong Yang; Qiuhong Chen; Xiaohui Li; Jingyi Guo
Journal:  Probiotics Antimicrob Proteins       Date:  2022-05-10       Impact factor: 4.609

2.  Identifying potential signatures for atherosclerosis in the context of predictive, preventive, and personalized medicine using integrative bioinformatics approaches and machine-learning strategies.

Authors:  Jinling Xu; Hui Zhou; Yangyang Cheng; Guangda Xiang
Journal:  EPMA J       Date:  2022-07-20       Impact factor: 8.836

3.  Therapeutic effects of different doses of prebiotic (isolated from Saccharomyces cerevisiae) in comparison to n-3 supplement on glycemic control, lipid profiles and immunological response in diabetic rats.

Authors:  Janina de Sales Guilarducci; Breno Augusto Ribeiro Marcelino; Isaac Filipe Moreira Konig; Tamira Maria Orlando; Mary Suzan Varaschin; Luciano José Pereira
Journal:  Diabetol Metab Syndr       Date:  2020-08-10       Impact factor: 3.320

4.  Assessment of the Safety of Lactobacillus casei IMV B-7280 Probiotic Strain on a Mouse Model.

Authors:  Lazarenko L M; Babenko L P; Gichka S G; Sakhno L O; Demchenko O M; Bubnov R V; Sichel L M; Spivak M Ya
Journal:  Probiotics Antimicrob Proteins       Date:  2021-04-20       Impact factor: 4.609

5.  Profiling of Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Obesity and Their Association With Ox-LDL and Hs-CRP in Adolescents.

Authors:  Abdur Rahman; Maha M Hammad; Irina Al Khairi; Preethi Cherian; Reem Al-Sabah; Fahd Al-Mulla; Mohamed Abu-Farha; Jehad Abubaker
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-28       Impact factor: 5.555

6.  In Vivo Healthy Benefits of Galacto-Oligosaccharides from Lupinus albus (LA-GOS) in Butyrate Production through Intestinal Microbiota.

Authors:  Lucila A Godínez-Méndez; Carmen M Gurrola-Díaz; José Sergio Zepeda-Nuño; Natali Vega-Magaña; Rocio Ivette Lopez-Roa; Liliana Íñiguez-Gutiérrez; Pedro M García-López; Mary Fafutis-Morris; Vidal Delgado-Rizo
Journal:  Biomolecules       Date:  2021-11-09

Review 7.  Material Engineering in Gut Microbiome and Human Health.

Authors:  Letao Yang; Lin Y Hung; Yuefei Zhu; Suwan Ding; Kara G Margolis; Kam W Leong
Journal:  Research (Wash D C)       Date:  2022-07-20

8.  Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial.

Authors:  Eun-Ji Song; Kyungsun Han; Tae-Joong Lim; Sanghyun Lim; Myung-Jun Chung; Myung Hee Nam; Hojun Kim; Young-Do Nam
Journal:  EPMA J       Date:  2020-02-07       Impact factor: 6.543

9.  Positive influence of gut microbiota on the effects of Korean red ginseng in metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Eunhak Seong; Shambhunath Bose; Song-Yi Han; Eun-Ji Song; Myeongjong Lee; Young-Do Nam; Hojun Kim
Journal:  EPMA J       Date:  2021-06-03       Impact factor: 8.836

Review 10.  Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine.

Authors:  Lenka Koklesova; Alena Liskova; Marek Samec; Tawar Qaradakhi; Anthony Zulli; Karel Smejkal; Karol Kajo; Jana Jakubikova; Payam Behzadi; Martin Pec; Pavol Zubor; Kamil Biringer; Taeg Kyu Kwon; Dietrich Büsselberg; Gustavo R Sarria; Frank A Giordano; Olga Golubnitschaja; Peter Kubatka
Journal:  EPMA J       Date:  2020-05-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.